In 2022, Xu Kelin’s research group employed molecular docking and screening in a compound library based on the crystal structure of the c-Myc/Max complex, and conducted experimental screening of the resulting compounds, leading to the identification of the most active compound D347-2761 (194) (best activity at 10 μM) (Table 3).474 In activity characterization experiment, D347-2761 bound to the DNA-binding region of Myc protein and demonstrated proliferation inhibitory activity on myeloma cells at 5–10 μM, with no inhibitory effect on normal cells. The gene discussed is MYC; the disease is plasma cell myeloma.